[New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
Soto Alvarez
J
J
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D015507:Drugs, Investigational / Q000191:economics; D005569:Formularies as Topic; D006801:Humans; D007449:Investments; D009313:National Health Programs / Q000191:economics*; D004364:Pharmaceutical Preparations / Q000191:economics*; D013030:Spain
D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations
Nuevos medicamentos en España: cuándo deberín ser considerados alternativas coste-efectivas e inversiones retnables para el Sistema de Salud Nacional?